Send us Feedback

CollaGenex Pharmaceuticals (CGPI)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Financials
SEC FILINGS

Topic Listing for CollaGenex Pharmaceuticals

Accounting Change Accounting Controls
Accounting Income Taxes Accounting Stock Issued Employees
Accredited Investor Accrued Expenses
Acknowledgements Acknowledgements Parties
Acknowledgment Acquired In-process Research Development
Acquired Licensed Intellectual Property Acquired Product Rights
Acquisition Actions Suits Proceedings
Additional Documents Additional Information
Additional Risks Affect Results Advertising Costs
Against Cardinal Health Only Written Approval Notwithstanding Foregoing Aggregated Option Exercises 2005 End Values
Agreement Agreement Act Placement Agent
Agreement Amended Read Follows Alcortin Novacort
Altana Amendment License Agreement
Amendments Articles Incorporation Bylaws Change Amendments Supplements Prospectus Supplement Other Matters
Appendix Applicable Registration Other Similar Rights
Approve Proposal Amend Amended Restated Certificate Incorporation Increase Approve Proposal Issue Greater 2900814 Shares Common Stock
Approved Investors Atridox Atrisorb Atrisorb-d Registered Trademarks Qlt Usa Inc
Atridox Atrisorb Freeflow Atrisorb-d Atrix
Audit Committee Audit Committee Board Directors
Audit Committee Pre-approval Policy Procedures Audit Committee Report
Audit Fees Audited Financial Statements
Auditors Fees Authorization
Authorization Contravention Authorization Sale Shares
Authorization Shares Avar
Barnett Base Salary
Basis Presentation Beardsley
Beneficial Ownership Reporting Compliance Benefits Other Compensation
Black Blue Sky Compliance
Blue Sky Nasd Matters Board Determination Independence
Board Directors Attendance Members Meetings Board Meetings Attendance
Body Shareholders Sansrosa Subject Agreement Document Indenture Other Broadbent
Business Cannot Assure Clinical Trials Completed Timely Manner Meet
Cannot Assure Pursuit Business Dermatology Market Successful Cannot Predict Certainty Effect Business Decline Revenues Generated
Cannot Rely Regulatory Protections Prevent Approval Generic Equivalents Capitalization Other Capital Stock Matters
Cardinal Healths Books Records Respect Processing Agreement Health Case Collagenex Mailed Notices Shall Addressed Corporate Headquarters
Cash Burn Cash Equivalents Short-term Investments
Cash Flows Management Cash Requirements Sources Uses
Cash Short Term Investments Cautionary Regarding Forward-looking Statements
Certain Additional Payments Employer Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certificate Amendment Amended Restated Incorporation Collagenex Pharmaceuticals Inc
Certification Certification Pursuant Rule 13a-14 15d-14 Exchange Act
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Change Address Account Please Check Box Right Indicate
Change Control Agreements Change Control Payments
Change Control Shall Mean Occurrence Following Events Changes
Changes Specifications Changes Stock Option Accounting Rules Significant Adverse Affect
Check Appropriate Box Below Form 8-k Filing Intended Clinical Developments Becocalcidiol
Clinical Developments Incyclinide Clinical Developments-col-118
Clinical Developments-incyclinide Clinical Developments-oracea Rosacea
Closing Code Business Conduct Ethics
Col-118 Collagenex
Collagenex International Ltd European Community Trademarks Collagenex International Ltd European Community United Kingdom Trademarks
Collagenex International Ltd Wholly-owned Subsidiary -united Kingdom Trademarks Collagenex International Ltd Wholly-owned Subsidiary United Kingdom Trademarks
Collagenex International Ltd-european Community Trademarks Collagenex International Ltd-european Community United Kingdom Trademarks
Collagenex Pharmaceuticals Announces Agreement Promote Collagenex Pharmaceuticals Inc
Collagenex Pharmaceuticals Inc Change Control Agreement Collagenex Pharmaceuticals Inc European Community Trademarks
Collagenex Pharmaceuticals Inc Index Consolidated Financial Statements Statement Collagenex Pharmaceuticals Inc Trademarks
Collagenex Pharmaceuticals Inc United States Trademarks Collagenex Pharmaceuticals Inc University Drive Newtown 18940
Collagenex Pharmaceuticals Inc-european Community Trademarks Collagenex Pharmaceuticals Inc-united States Trademarks
Commercial Manufacturing Agreement Commercial Manufacturing Distribution Suppliers
Commitments Commitments Contingencies
Committees Common Stock Collagenex Pharmaceuticals Inc
Common Stock Directors Common Stock Offering
Common Stock Par Value 001 Per Share Corporation Communicating Independent Directors
Communications Stockholders Compensation Chief Executive Officer
Compensation Committee Board Directors Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Executive
Compensation Mix Competition
Compliance Applicable Regulations Compliance Certificate
Compliance Prospectus Delivery Requirements Compliance Registration Requirements Stop Order Objection Nasd
Comply Applicable Regulations Relating Development Manufacture Promotion Marketing Concentration Credit Other Risks
Conditions Each Series Holders Obligations Closing Conditions Obligations Closing
Conditions Obligations Placement Agent Conference Call
Conference Call Information Conference Call Scheduled 1100 Edt Today
Confidential Information Confidentiality
Confirmation Sale Consent Independent Registered Public Accounting Firm
Consent Jurisdiction Consents Approvals Authorizations Required
Contact Contingent Otherwise Other Those Incurred Ordinary Course Business
Contract Contract License Revenues
Contract Revenue Contract Revenues
Contractual Obligations Contribution
Controls Procedures Copies Amendments Supplements Prospectus Supplement
Corporate Governance Guidelines Corporate Proceedings
Cost Product Sales Counterparts
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies Estimates
Current Competitive Position Dental Marketplace Depends Successfully Enforcing Current Report Pursuant Securities Exchange Act 1934
Currently Marketed Dermatology Products Customer Product Concentrations
Customers Backlog Daverman
Defaults Violations Deferred Taxes
Definition Terms Following Referred Agreement Shall Meanings Definitions
Delays Omissions Delivery
Delivery Funds Delivery Payment
Delivery Shares Denavir
Dental Departure Directors Principal Officers Election Appointment
Depend Certain Key Relationships Generate Much Technology Required Depend Party Researchers Providers Clinical Services Perform Contractually
Depending Heavily Commercial Success Oracea Unable Commercialize Successfully Depending Heavily Commercial Success Oracea Unable Successfully Commercialize
Depending Heavily Success Most Advanced Product Candidate Oracea Dermatology
Dermatology Products Determination Independence
Development Director Attendance Annual Meeting Stockholders
Director Candidates Director Compensation
Director Nomination Process Directors Executive Officers Corporate Governance
Disclosure Controls Procedures Discretionary Cash Bonus
Distribution Offering Material Dividends
Doxycycline Delayed Release Pellets Doxycycline Immediate Release Pellets
Each Succeeding Event Shall Shareholders Further Financial Responsibility Earnings Statement
Easton Election Directors
Employees Employment Contracts Termination Change-in-control Arrangements
Employment Severance Change Control Arrangements Employment Taxes Payments Pursuant Agreement Shall Subject Withholding
Enforceability Entire Agreement
Entry Material Definitive Agreement Equipment Leasehold Improvements
Equity Compensation Plan Information Exact Name Registrant Specified Charter
Example Calculation Gross Profit Excess Inventory
Exchange Act Reports Filed Executive Compensation
Executive Compensation Policy Executive Director Compensation Processes
Executive Officer Compensation Summary Executive Officers
Exhibits Extension Amendment Promotion Cooperation Agreement
Family Relationships Fda
Federal Regulatory Status Alcortin Novacort Changes Unable Continue Fifth Loan Modification Agreement
Filing Certificate Designation Final Paragraphs Identified Payment Submission Pos Agreement Amended
Financial Guidance Financial Instruments
Financial Statement Schedule Financial Statements Exhibits
Financial Statements Supplementary Data Ford
Form 10-k Form 10-k Amendment
Form 10-q Form 8-k
Form Subscription Agreement Former Name Address Changed Since Last Report
Forward Looking Statements Forward-looking Statements
Fully Paid Non-assessable Shares Common Stock Par Value Further Covenants
Future Competitive Position Marketplace Depends Obtaining Enforcing Successfully Future Payments Purchase Price Installments Whether Base Consideration
Gain Sale European Dental Assets General
General Provisions Generic Version Periostat Other Mutuals Branded Becomes Available
Governing Law Governing Law Jurisdiction
Governing Law Provisions Government Regulation
Governmental Authorization Party Consents Grant
Grant Revenues Grants Plan-based Awards
Guidance Headings
Held 2007 Holders
Householding Annual Meeting Materials Impacs
Impairment Long-lived Assets In-licensed Technology-becocalcidiol
Income Taxes Incorporation Good Standing
Incyclinide Acne Indemnification
Indemnification Contribution Indemnification Directors Officers
Indemnification Placement Agent Independent Accountants
Independent Registered Public Accounting Firms Fees Other Matters Index
Information Contained Report Fairly Presents Material Respects Financial Information Provided Placement Agent
Infringe Alleged Intellectual Property Rights Parties Adversely Affect Insurance
Intangible Assets Intangible Assets Net
Intellectual Property Intellectual Property Rights
Interest Income Interest Income Expense
Internal Controls Over Financial Reporting Introductory
Inventories Inventory
Inventory Costs Amendment Arb Chapter Investment
Investor Questionnaire Involvement Certain Legal Proceedings
Ivax Corepharma Labor Matters
Lasezkay Legal Expenses Defend Periostat Patents
Legal Proceedings Legal Settlements Proceedings
Legends Letter Credit Foreign Exchange Contract Cash Management Services
License Revenue Licensing Co-promotion Agreements
Limitations Liability Line Credit
Lose Sole Supplier Doxycycline Hyclate Current Manufacturer Periostat Lose Sole Supplier Doxycycline Manufacturer Oracea Sales Interrupted
Management Estimates Manufacturing Distribution Suppliers
Market Information Market Registrants Common Equity Related Stockholder Matters Issuer
Marketing Expenses Include Personnel Salaries Benefits Managed Care Material Adverse Change
Material Modification Rights Security Holders Materials
Medigene Merck
Merger Agreement Galderma Pharma Minimum Commitment Purchase Orders Forecasts
Minimum Liquidity Minimum Royalties
Minimum Sales Miscellaneous
Miscellaneous Provisions Mutual
Necessary Permits Etc Need Substantial Additional Funding Unable Raise Capital Needed
Need Substantial Funding Unable Raise Additional Capital Needed Net Cash Provided Financing Activities
Net Cash Used Investing Activities Net Cash Used Operating Activities
Net Cash Used Provided Financing Activities Net Cash Used Provided Investing Activities
Net Loss Net Loss Allocable Common Stockholders
Net Loss Income Per Share Net Product Sales
New Drug Application Nda Oracea Filed Fda 2005 Newtown 2005
Newtown 2006 Newtown 2007
Newtown 2008 Nominating Corporate Governance Committee Board Directors
Non-contravention Existing Instruments Agreements Non-employee Director Compensation
Non-management Director Compensation Not Able Obtain Enforce Patent Protection Oracea Other
Not Able Obtain Required Regulatory Approvals Commercialize Product Not Applicable
Not Investment Notice
Notice Annual Meeting Stockholders Held 2006 Notices
Notices Etc Notifications Other Indemnification Procedures
Now Therefore Number 0-28308
Number 000-28308 Offering Materials Furnished Placement Agent
Officers Certificate Opinion Counsel
Option Exercises Stock Vested Option Grants 2005
Option Not Exercised Fraction Share Optional Redemption
Oracea Oshea
Other Commitments Other Commitments Contingencies
Other Events Other Impacs Activities
Other Income Expense Other Information
Other Matters Other Product Offering
Other Product Offerings Other Provisions Agreement Shall Remain Full Force Effect
Other Trade Names Trademarks Service Marks Property Respective Outstanding Equity Awards Year-end
Oversight Independent Auditor Overview
Overview Philosophy Ownership
Pandel Part Product Specifications Quality Laboratory Test Results
Partial Unenforceability Parties
Patents Patents Trade Secrets Licenses
Payment Expenses Pension Benefit Plans Sansrosa Party Respect Ongoing Future
Performance Graph Performed Agreement Constitutes Valid Obligation Collagenex Legally Binding
Periodic Reporting Obligations Periostat
Perquisites Pfeiffer
Placement Agency Agreement Please Date Sign Return Proxy Card Earliest Convenience
Please Indicate Compliance Status Circling Yes Complies Column Please Sign Date Return Promptly Enclosed Envelope Vote
Policies Procedures Related Person Transactions Powell
Pre-launch Manufacturing Costs Preclinical Other Research Development Activities
Preferred Stock Agreements Preferred Stock Collagenex Pharmaceuticals Inc
Preferred Stock Dividend Preferred Stock Dividend Series D-1 Restructuring Exchange
Preferred Stock Dividend Series Restructuring Exchange Preferred Stock Purchase Rights 001 Par Value
Preferred Stockholders Not Approve Research Development Expenditures Business Preparation Financial Statements
Press Release Previously Marketed Product
Previously Marketed Products Price Stabilization Manipulation
Pricing Payment Primus
Principal Accountant Fees Services Principles Consolidation
Prior Contemporaneous Agreements Whether Written Oral Respect Agreement Proceeds
Product Data Referenced Rma Product Rights Oracea Milestone Fees Stated Cost Amortized
Product Rights Stated Cost Amortized Over Shorter Estimated Products Cause Injuries Incur Significant Expense Liability
Products Development Subject Extensive Regulation Fda Products Subject Restrictions Withdrawal Market Penalties Fail Comply
Properties Provided However
Proxy Statement Qlt Usa Inc
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Data
Quarterly Period 2005 Quatrx
Ratification Selection Independent Registered Public Accounting Firm Recent Announcements
Recent Highlights Recent Sales Unregistered Securities
Recently Issued Accounting Pronouncements Recently Issued Accounting Standards
Recitals Reclassification
Records Regulatory Matters Registrants Telephone Number Including Area Code
Registration Statement Matters Reimbursement Placement Agents Expenses
Related Party Transactions Releases
Rely Product Periostat Mutuals Branded Version Most Revenue Remainder Page Intentionally Left Blank
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Reports Documents Etc Representations Indemnities Survive Delivery
Representations Warranties Representations Warranties Covenants Investor
Research Development Research Development Expense
Research Development Expenses Resolved
Restoraderm Restructuring
Restructuring Exchange Agreement Results Operations
Results Operations Financial Condition Retirement
Revenue Recognition Revenues
Review Other Financial Disclosures Revised 2006 Financial Guidance
Revised 2007 Financial Guidance Right Exercise
Role Chief Executive Officer Compensation Decisions Rosacea
Salary Reduction Plan Sale European Dental Assets
Sales Force Restructuring Sales Marketing
Sarbanes-oxley Act 2002 Schedule
Schedule Sub-license Agreement Sections Agreement Amended Read Follows
Securities Exchange Act 1934 Securities Law Filings
Security Ownership Certain Beneficial Owners Management Related Stockholder See
Segment Information Selling General Administrative
Selling General Administrative Expense Selling General Administrative Expenses
Series D-1 Preferred Stock Director Services
Services Fee Schedule Settlements
Severability Severance Benefits Event Involuntary Termination
Share Purchase Agreement Share-based Compensation
Share-based Payment Signature
Signature Page Follows Signatures
Significant Recent Developments Silicon Valley Bank
Sixth Loan Modification Agreement Small Number Wholesale Customers Mutual Account Majority Sales
Soon Possible Specifications
Stewart Stock Exchange Listing
Stock Option Agreement Stock Options
Stock Price Highly Volatile Therefore Value Investment Fluctuate Stock-based Compensation
Stockholders Equity-common Stock Stockholders Proposals
Stop Order Sub-license Agreement
Submission Matters Vote Security Holders Subscription
Subscription Agreement Subsequent Events
Subsidiaries Successors
Successors Assigns Assignment Summary Compensation 2005 2004 2003
Survival Representations Warranties Agreements Party Beneficiary Table Contents
Tangible Net Worth Shall Exclude Deferred Licensing Fees Tax Accounting Considerations
Tax Considerations Tax Fees
Tax Law Compliance Technology
Technology License Technology-impacs
Technology-restoraderm Technology-sansrosa
Term Agreement Extended Until 2008 Accordingly Amended Read Term Termination
Term Termination Remedies Termination
Termination Date Shall Mean Effective Notice Delivered Party Termination Either Party
Termination Material Definitive Agreement Testing Samples Release
Theobald Third-party Payors Not Adequately Reimburse Customers Approved Products
Thirty-one Timing Payments Indemnification
Timing Pricing Option Grants Title Properties
Total Annual Fee Services Provided Gross Purchases Total Net Revenues
Total Revenues Transactions Contemplated Hereby Been Duly Satisfied Waived Accordance
Transfer Agent Transfer Taxes Other Fees
Transition Election Related Accounting Tax Effects Share-based Payment Unable Raise Additional Capital Needed Force Delay Reduce
Unit Pricing Fees Minimum Requirement Unregistered Sales Equity Securities
Untrue Omits Omitted Material Fact Necessary Make Statement Updated 2007 Financial Guidance
Valid Issuance Series D-1 Preferred Validation Processing Related Services
Vioxx Wall Street Journal
Whereas Witness Whereof
Wwwcollagenexcom 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki